Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential

Cyclic 3′5′-guanosine monophosphate (cGMP) is a key second messenger involved in the processes of intracellular signalling. Steady state levels of cGMP are modulated through a balance between the rates of formation and degradation of the nucleotide. A potential therapeutic approach to manipulation of cGMP is the inhibition of the phosphodiesterases PDE1 and PDE5. PDE5 inhibitors have been targeted by many companies and have resulted in a large number of patents. The disclosed inhibitors cover an eclectic range of polycyclic nitrogen heterocycles. Activities reported show IC50 values in the low nanomolar to subnanomolar range. A wide range of tissue, cellular and in vivo effects are also reported for these PDE5 inhibitors. By contrast, only a very few patents have appeared which claim PDE1 inhibitory activity. The potential use of PDE1 and PDE5 inhibitors in the treatment of coronary artery disease, hypertension, congestive heart failure, erectile dysfunction and pulmonary hypertension is discussed.

[1]  L. Rubin,et al.  Primary pulmonary hypertension. , 1997, The New England journal of medicine.

[2]  P. Chiu,et al.  Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor, in guinea pigs , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  L. Hung,et al.  cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. , 1997, Circulation.

[4]  D. Hlasta,et al.  Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I) , 1997 .

[5]  A. Pappano,et al.  Biphasic effects of intrapipette cyclic guanosine monophosphate on L-type calcium current and contraction of guinea pig ventricular myocytes. , 1996, The Journal of pharmacology and experimental therapeutics.

[6]  D. Tulshian,et al.  Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. , 1996, Journal of cardiovascular pharmacology.

[7]  T. Suzuki,et al.  A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. , 1996, Life sciences.

[8]  F. Murad.  Signal Transduction Using Nitric Oxide and Cyclic Guanosine Monophosphate , 1996 .

[9]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[10]  J C Gingell,et al.  Sildenafil, a novel effective oral therapy for male erectile dysfunction. , 1996, British journal of urology.

[11]  N. Hartell,et al.  Inhibition of cGMP Breakdown Promotes the Induction of Cerebellar Long-Term Depression , 1996, The Journal of Neuroscience.

[12]  N. Dodic,et al.  Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones. , 1996, Journal of medicinal chemistry.

[13]  M. Czarniecki,et al.  Chapter 7. Inhibitors of Types I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy , 1996 .

[14]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications. , 1996, Advances in pharmacology.

[15]  K. Yau,et al.  Cyclic nucleotide-gated ion channels: an extended family with diverse functions. , 1996, Annual review of physiology.

[16]  M. Frierson,et al.  Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2‐Pyridyl‐ and 2‐Imidazolylquinazolines Possessing Cyclic GMP Phoshodiesterase and Thromboxane Synthesis Inhibitory Activities. , 1995 .

[17]  T. Saeki,et al.  A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  H. Adachi,et al.  Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs. , 1994, European journal of pharmacology.

[19]  A. Struthers,et al.  Fortnightly Review: Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? , 1994 .

[20]  F. Murad,et al.  Effects of cyclic GMP on smooth muscle relaxation. , 1994, Advances in pharmacology.

[21]  A. Vaandrager,et al.  Effect of cyclic GMP on intestinal transport. , 1994, Advances in pharmacology.

[22]  H. Masuda,et al.  Cyclic GMP regulation of calcium slow channels in cardiac muscle and vascular smooth muscle cells. , 1994, Advances in pharmacology.

[23]  J. Karlsson,et al.  Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma. , 1993, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[24]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[25]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Mehta,et al.  Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor. , 1989, The Journal of pharmacology and experimental therapeutics.